CN109384765A - 逆转录酶抑制剂的晶型 - Google Patents

逆转录酶抑制剂的晶型 Download PDF

Info

Publication number
CN109384765A
CN109384765A CN201811295039.5A CN201811295039A CN109384765A CN 109384765 A CN109384765 A CN 109384765A CN 201811295039 A CN201811295039 A CN 201811295039A CN 109384765 A CN109384765 A CN 109384765A
Authority
CN
China
Prior art keywords
methyl
oxo
compound
hiv
anhydrous form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811295039.5A
Other languages
English (en)
Chinese (zh)
Inventor
C.K.马圭尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN109384765A publication Critical patent/CN109384765A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201811295039.5A 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型 Pending CN109384765A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261705780P 2012-09-26 2012-09-26
US61/705780 2012-09-26
CN201380050220.9A CN104684557A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201380050220.9A Division CN104684557A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形

Publications (1)

Publication Number Publication Date
CN109384765A true CN109384765A (zh) 2019-02-26

Family

ID=50388877

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201811295039.5A Pending CN109384765A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶型
CN201380050220.9A Pending CN104684557A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201380050220.9A Pending CN104684557A (zh) 2012-09-26 2013-09-20 逆转录酶抑制剂的晶形

Country Status (9)

Country Link
US (1) US9150539B2 (https=)
EP (1) EP2900240B1 (https=)
JP (2) JP6387349B2 (https=)
CN (2) CN109384765A (https=)
BR (1) BR112015005997A8 (https=)
CA (1) CA2882947A1 (https=)
ES (1) ES2773105T3 (https=)
MX (1) MX362517B (https=)
WO (1) WO2014052171A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016012658B1 (pt) 2013-12-04 2022-06-21 Merck Sharp & Dohme Corp Métodos para sintetizar inibidores da transcriptase reversa e composto
WO2018175271A1 (en) * 2017-03-24 2018-09-27 Merck Sharp & Dohme Corp. Formulation for parenteral administration
KR20220130698A (ko) * 2019-12-20 2022-09-27 에피자임, 인코포레이티드 Ezh2 억제제의 결정질 하이드로브로마이드 염, 이의 제조 및 암의 치료에 유용한 약학적 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938306A (zh) * 2004-04-02 2007-03-28 贝林格尔·英格海姆国际有限公司 5,11－二氢－11－乙基－5－甲基－8－{2－{(1－氧－4－喹啉基)氧基}乙基}－6H－二吡啶并[3,2－b:2′,3′－e][1,4]二氮杂䓬－6－酮的晶形
US20110245296A1 (en) * 2010-03-30 2011-10-06 Jason Burch Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0513858B8 (pt) * 2004-07-27 2021-05-25 Hoffmann La Roche compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
BR122021006634B1 (pt) * 2007-05-30 2022-03-29 F. Hoffmann-La Roche Ag Processo para preparação de triazolonas
KR20100088142A (ko) * 2007-11-20 2010-08-06 머크 샤프 앤드 돔 코포레이션 비-뉴클레오사이드 역전사효소 억제제

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1938306A (zh) * 2004-04-02 2007-03-28 贝林格尔·英格海姆国际有限公司 5,11－二氢－11－乙基－5－甲基－8－{2－{(1－氧－4－喹啉基)氧基}乙基}－6H－二吡啶并[3,2－b:2′,3′－e][1,4]二氮杂䓬－6－酮的晶形
US20110245296A1 (en) * 2010-03-30 2011-10-06 Jason Burch Non-nucleoside reverse transcriptase inhibitors
WO2011126969A1 (en) * 2010-04-08 2011-10-13 Merck Sharp & Dohme Corp. Prodrugs of an hiv reverse transcriptase inhibitor

Also Published As

Publication number Publication date
CN104684557A (zh) 2015-06-03
MX2015003767A (es) 2015-07-14
US9150539B2 (en) 2015-10-06
EP2900240A4 (en) 2016-07-13
WO2014052171A1 (en) 2014-04-03
US20150232447A1 (en) 2015-08-20
JP6387349B2 (ja) 2018-09-05
EP2900240A1 (en) 2015-08-05
JP2018024683A (ja) 2018-02-15
EP2900240B1 (en) 2020-01-08
JP2015531372A (ja) 2015-11-02
BR112015005997A8 (pt) 2023-04-11
ES2773105T3 (es) 2020-07-09
CA2882947A1 (en) 2014-04-03
BR112015005997A2 (pt) 2017-07-04
MX362517B (es) 2019-01-21

Similar Documents

Publication Publication Date Title
AU2019208331C1 (en) Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors
TWI847144B (zh) 奧美卡替莫卡必爾的合成
KR20220008273A (ko) 암 치료를 위한 raf 억제제로서의 n-(3-(2-(2-하이드록시에톡시)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-2 (트리플루오로메틸)이소니코틴아미드의 새로운 결정질 형태
WO2008157273A1 (en) Chemical compounds
MX2012009964A (es) Sales cristalinas de un potente inhibidor del hcv.
CN110678178A (zh) Mk2抑制剂的形式和组合物
JP2022536489A (ja) ６－（シクロプロパンカルボキサミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキサミドの結晶性塩形態
CN109384765A (zh) 逆转录酶抑制剂的晶型
WO2001043742A1 (en) Novel processes for making- and a new crystalline form of- leflunomide
WO2012014149A1 (en) N-methylformamide solvate of dasatinib
CN115215857A (zh) 硫酸艾沙康唑的制备方法
JP2018030884A (ja) テノホビルの固体形態
WO2016172333A1 (en) A solid state form of perampanel
CN111484488A (zh) 一种b-raf激酶二聚体抑制剂的稳定结晶形式a
CN103772413A (zh) 一种利福平ⅱ晶型的制备方法
CN105523994B (zh) 甲磺酸洛美他派晶型iii
CN109134471B (zh) 一种苯并二氮杂*化合物的固态形式及其制备方法和应用
WO2023134769A1 (zh) 4'-取代核苷的晶体、其制备方法、组合物和用途
US20250074934A1 (en) Crystal of 4’-substituted nucleoside, and preparation method therefor, composition thereof and use thereof
CN101611024A (zh) 芳基-取代的吡唑-酰胺化合物的晶形
WO2011016044A1 (en) Novel polymorphs of adefovir dipivoxil
CN121773096A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的l-赖氨酸盐及其各种形式
CN121646582A (zh) 4-氯-5-[4-(2,6-二氯苯基)磺酰基哌嗪-1-基]-1-苯并呋喃-2-甲酸的氨丁三醇盐及其各种形式
CA2566803A1 (en) Drying process for preparing crystalline solid famciclovir
TW202600558A (zh) 醛固酮合成酶抑制劑之固體形式

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20220902

Address after: new jersey

Applicant after: MERCK SHARP & DOHME B.V.

Address before: new jersey

Applicant before: MERCK SHARP & DOHME Corp.

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20190226